PF-562271 HCl: Precision FAK/Pyk2 Inhibitor for Cancer Research

Principle and Experimental Setup: Harnessing ATP-Competitive FAK Inhibition

PF-562271 HCl stands at the forefront of cancer research tools as a potent, ATP-competitive, and reversible focal adhesion kinase (FAK) inhibitor. By selectively targeting both FAK (IC₅₀ = 1.5 nM) and its homolog proline-rich tyrosine kinase 2 (Pyk2; IC₅₀ = 14 nM), PF-562271 HCl enables researchers to dissect the focal adhesion kinase signaling pathway with unparalleled specificity while sparing most off-target kinases. FAK and Pyk2 are central to cellular adhesion, migration, and survival, making them prime targets in studying tumor growth inhibition, metastatic spread, and tumor microenvironment modulation.

Supplied as a solid, PF-562271 HCl should be stored at -20°C. For experimental use, it is soluble at ≥26.35 mg/mL in DMSO with gentle warming, but insoluble in water and ethanol. This property facilitates its integration into both in vitro and in vivo workflows, provided appropriate vehicle controls are employed. As a gold-standard FAK/Pyk2 inhibitor from APExBIO, it empowers investigations ranging from basic mechanistic studies to translational oncology and immunotherapeutic strategy development.

Step-by-Step Workflow and Protocol Enhancements

1. Compound Preparation and Handling

• Reconstitution: Dissolve the supplied PF-562271 HCl powder in DMSO to create a concentrated stock solution (e.g., 10 mM). Gentle warming (≤37°C) may be applied to aid solubilization; avoid exceeding this temperature to maintain compound integrity.
• Aliquoting: To prevent degradation from repeated freeze-thaw cycles, aliquot stock solutions and store at -20°C. For optimal performance, use freshly prepared solutions and avoid long-term storage.
• Working Dilutions: Dilute stock solutions in culture media or buffer immediately before use. For in vitro studies, ensure the final DMSO concentration does not exceed 0.1–0.2% to minimize cytotoxicity.

2. In Vitro FAK/Pyk2 Inhibition Assays

• Cell Seeding: Plate adherent cancer cell lines (e.g., MDA-MB-231, A549) at appropriate densities to reach 70–80% confluency within 24 hours.
• Treatment: Treat cells with serial dilutions of PF-562271 HCl (ranging from 0.1 nM to 1 μM) to establish dose-response curves. Control wells should include vehicle (DMSO) only.
• Readouts: Assess FAK phosphorylation inhibition by Western blotting or ELISA for p-FAK (Tyr397) after 2–24 hours of treatment. For functional assays, monitor migration (scratch/wound-healing assay), invasion (Matrigel transwell), or viability (MTT/XTT assays).
• Data Analysis: Quantify IC₅₀ values for FAK and Pyk2 inhibition. PF-562271 HCl typically produces an EC₅₀ for p-FAK inhibition in the low nanomolar range, with full suppression at ≤100 nM in most cell lines.

3. In Vivo Tumor Growth and Metastasis Models

• Dosing: Formulate PF-562271 HCl in a vehicle suitable for animal studies (e.g., 10% DMSO, 40% PEG-300, 5% Tween-80, 45% saline). Administer by oral gavage or intraperitoneal injection as per experimental design.
• Regimen: For xenograft models, initiate treatment once tumors reach 100–200 mm³. Typical dosing regimens range from 25–125 mg/kg daily, with durable FAK phosphorylation inhibition observed at plasma concentrations ≥93 ng/mL.
• Endpoints: Monitor tumor volume, metastasis incidence (e.g., via bioluminescence imaging), and animal weight. Collect tumor and metastatic tissues for downstream analysis of FAK pathway inhibition and microenvironment modulation.

Advanced Applications and Comparative Advantages

PF-562271 HCl’s high selectivity and reversible inhibition profile enable a spectrum of advanced applications in cancer research:

• Tumor Microenvironment Modulation: By inhibiting FAK/Pyk2, researchers can probe alterations in stromal cell recruitment, angiogenesis, and immune cell infiltration within the tumor microenvironment. This complements findings from studies like Adams et al. (2025), which highlight the interplay of myeloid progenitor cells in pre-metastatic niche formation and metastatic progression.
• Metastatic Niche Dissection: PF-562271 HCl is uniquely positioned to interrogate the ‘seed and soil’ hypothesis by blocking FAK/Pyk2-driven migratory and invasive programs in circulating tumor cells (CTCs) and polyploid giant cancer macrophages (PGCCs/CAMLs), as described in the referenced study.
• Synergistic Drug Combinations: Its robust selectivity profile enables combination with immunotherapies, chemotherapeutics, or anti-angiogenic agents to unravel cooperative or antagonistic mechanisms in tumor growth inhibition.
• Functional Genomics Screens: As detailed in this article, PF-562271 HCl enhances functional genomics workflows by serving as a precise tool for pathway validation and off-target effect minimization—contrasting with broader-spectrum kinase inhibitors that confound data interpretation.
• Immunomodulatory Investigations: Recent analyses demonstrate the compound’s value in modulating immune cell recruitment and activation, extending its utility beyond traditional proliferation or migration assays.

Compared to earlier-generation FAK inhibitors, PF-562271 HCl offers nanomolar potency, 10-fold selectivity for FAK over Pyk2, and >100-fold selectivity over most kinases (excluding some CDKs), thereby reducing off-target effects and enhancing translational relevance. For a deeper dive into protocols and comparative performance, see this resource, which details actionable protocols and workflow optimizations.

Troubleshooting and Optimization Tips

• Solubility Issues: If the compound fails to dissolve fully in DMSO, ensure gentle warming and vortexing. Avoid excessive heat, which can compromise activity.
• Precipitation in Media: When diluting into aqueous buffers or media, add PF-562271 HCl stock solution dropwise with vigorous mixing. Pre-warm media to 37°C to aid dispersion. If precipitation persists, increase DMSO percentage slightly (up to 0.2%) but verify cell line tolerance.
• Batch Variability: Always verify batch purity and confirm IC₅₀ values with control phosphorylated substrates. APExBIO provides rigorous lot-to-lot consistency, but in-house validation is recommended for critical assays.
• FAK Phosphorylation Readouts: Use validated antibodies and positive/negative controls for p-FAK and p-Pyk2. Time-course experiments help distinguish direct versus compensatory pathway effects.
• In Vivo Dosing: Monitor animal health closely, as high systemic concentrations can induce off-target effects in sensitive models. Adjust dosing frequency or concentration based on pharmacokinetic data and target EC₅₀ (e.g., 93 ng/mL for p-FAK inhibition in tumor-bearing mice).
• Data Interpretation: In functional assays, include appropriate negative (vehicle) and positive (alternative FAK inhibitor) controls to ensure specificity of observed effects.

Future Outlook: Expanding the Frontier of FAK/Pyk2-Targeted Cancer Research

With the emergence of data implicating FAK/Pyk2 signaling in both tumor cell-intrinsic and microenvironmental processes—including immune modulation, angiogenesis, and metastatic niche formation—PF-562271 HCl is poised to remain a cornerstone for next-generation oncology research. Its unique value is particularly evident in studies like Adams et al. (2025), where dissecting the interaction between myeloid progenitor cells and tumor progression hinges on precise pathway inhibition.

Future investigations will likely expand into combinatorial therapy design, leveraging PF-562271 HCl’s selectivity to synergize with immunotherapies and targeted agents. Integration with high-content imaging, single-cell sequencing, and spatial transcriptomics will further unveil the compound’s impact on the tumor microenvironment and cell migration dynamics. As translational oncology seeks to bridge bench and bedside, tools like PF-562271 HCl—available via APExBIO’s PF-562271 HCl product page—will be instrumental in both mechanistic discovery and preclinical validation.

For a comprehensive overview of the compound’s role in immunomodulation and functional genomics, and to compare its performance with other pathway inhibitors, readers are encouraged to explore the latest comparative studies. These insights collectively position PF-562271 HCl as a gold-standard reversible focal adhesion kinase inhibitor for advancing cancer research and therapeutic innovation.